Biosimilar Maker Leverages IPR to Avoid Patent Dance and Obtain Early Market Entry
Bio Law Blog
JUNE 21, 2020
On May 28, Alexion and Amgen entered into a confidential settlement agreement to terminate the IPRs. Pursuant to the terms of the settlement agreement, effective March 1, 2025 (or earlier in certain circumstances), Alexion grants to Amgen a nonexclusive, royalty-free license under U.S. an eculizumab product.
52 
Let's personalize your content